Endometrial Cancer: Adjuvant Taxane Plus Platinum Agent Does Not Improve Outcomes
A study concluded that adjuvant therapy with a taxane and a platinum agent was not superior over standard therapy for women with high-risk endometrial cancer.
|The following article features coverage from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Click here to read more of Cancer Therapy Advisor's conference coverage.|
The JGOG2043 study concluded that adjuvant therapy with a taxane and a platinum agent was not superior over standard therapy with doxorubicin and cisplatin (AP) for women with high-risk endometrial cancer, according to data reported at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.1
Data from JGOG2043 were presented by Hiroyuki Nomura, MD, of Keio University in Japan. Progression-free survival (PFS) and overall survival (OS) were similar for patients receiving adjuvant docetaxel and cisplatin (DP) or paclitaxel and carboplatin (TC) compared with AP.
In this study, 788 women with endometrial cancer with a high risk for recurrence (stage I/II with G2/G3 and a myometrial invasion greater than 2 cm, stage III, and stage IV with no metastatic lesion beyond the abdominal cavity) and postoperative residual disease (less than 2 cm) were randomly assigned (1:1:1) to receive AP (263 patients), DP (263 patients), or TC (262 patients).
More than 75% of patients in each group received 6 cycles of treatment.
After a median follow up of 7.0 years, there was no significant difference in PFS or OS between the 3 groups. Five-year PFS rates were 74.5% for the AP group, 80.5% for the DP group, and 74.3% for the TC group (P = .1246). Corresponding 5-year OS rates were 83.9%, 88.9%, and 88%, respectively (P = .6734).
Dr Nomura noted that toxicities in each arm were acceptable. Hematologic toxicities were more common with AP while those with the taxane and platinum regimens were generally mild.
RELATED: Cabozantinib Evaluated in Aggressive Endometrial Cancer Subtype
“A regimen with a taxane plus platinum agent may be a reasonable alternative to AP,” Dr Nomura concluded.
Read more of Cancer Therapy Advisor's coverage of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting by visiting the conference page.
- Nomura H, Aoki D, Michimae H, et al. A randomized phase III trial of docetaxel plus cisplatin or paclitaxel plus carboplatin compared with doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at a high risk for recurrence: Japanese Gynecologic Oncology Group study (JGOG2043). J Clin Oncol. 2017;34(suppl; abstr 5503).